Formycon - FY19 results – strong position, new projects
Formycon ended 2019 with a strong €22.4m cash position and three main projects. A new project to manufacture antibodies against SARS-CoV-2 is...
171 Views
Formycon - FYB201 FDA filing imminent
Formycon's partner Bioeq IP plans to file FYB201, a Lucentis biosimilar candidate, to treat neovascular age-related macular degeneration (nAMD)...
857 Views
Formycon - H119 results – FYB201 FDA filing imminent
Formycon's partner Bioeq IP (Bioeq) plans to file FYB201, a Lucentis biosimilar candidate, to treat neovascular age-related macular degeneration...
1k Views
Formycon - H118 results: FYB201 registration closer
Formycon has reported record H118 revenues, boosted by the one-off transfer of FYB202 into a joint venture with Aristo Pharma and payments stemming...
89 Views
Formycon - Lucentis biosimilar scores Phase III success
Formycon has announced that its Lucentis biosimilar FYB201 showed comparable efficacy with branded Lucentis in a global Phase III study in nAMD....
80 Views